warning

Alert: Because flu cases are on the rise, children 12 and younger will be restricted from visiting hospitals and certain inpatient facilities. Learn more.

Research and Clinical Trials

Title  
Janssen 54767414MMY1001: An Open-label, Multicenter, Phase 1b Study of JNJ-54767414 (HuMax® CD38) (Anti-CD38 Monoclonal Antibody) in Combination with Backbone Regimens for the Treatment of Subjects with Multiple Myeloma
Brief Description  
Primary Objective: The primary objective of the study is to evaluate the safety, tolerability (including dose-limiting toxicity [DLT]), and dosing of daratumumab when administered to subjects with multiple myeloma in combination with various treatment regimens: VELCADE-dexamethasone (VD), VELCADE-melphalan-prednisone (VMP), pomalidomide-dexamethasone (Pom-dex), and VELCADE-thalidomide-dexamethasone (VTD). Additional Primary Objectives added to Amendment INT-5: The primary objective of the carfi
Who may be Eligible  
Please contact us for eligibility criteria.
Speciality/Disorder  
Multiple Myeloma
Status  
OPEN
Start Date  
04/05/2016
IRB Number  
00016751
Principal Investigator  
Usmani, Saad Zafar
Contact Name  
Tesa M Adams

For More Information, Contact  Tesa  M, Adams
Phone:  980-442-2335 Fax:    
Email:  Tesa.Adams@carolinashealthcare.org
Address:1021 Morehead Medical Drive Suite 2200 Charlotte, NC 28204
Close